To date, no standard of care for second-line therapy advanced pancreatic adenocarcinoma has been established patients progressing on first-line FOLFIRINOX or Gemzar/Abraxane. [1] The use a modified regimen Gemcitabine, Docetaxel, and Capecitabine (GTX) suggested following considerable evidence which showed GTX-induced synergistic apoptosis human cancer cells. [2] Retrospective analysis GTX use,...
